Biological Effects of Polysaccharides from Bovistella utriformis as Cytotoxic, Antioxidant, and Antihyperglycemic Agents: In Vitro and In Vivo Studies.
Aya Maaloul, Claudia Pérez Manríquez, Juan Decara, Manuel Marí-Beffa, Daniel Álvarez-Torres, Sofía Latorre Redoli, Borja Martínez-Albardonedo, Marisel Araya-Rojas, Víctor Fajardo, Roberto T Abdala Díaz
{"title":"Biological Effects of Polysaccharides from <i>Bovistella utriformis</i> as Cytotoxic, Antioxidant, and Antihyperglycemic Agents: In Vitro and In Vivo Studies.","authors":"Aya Maaloul, Claudia Pérez Manríquez, Juan Decara, Manuel Marí-Beffa, Daniel Álvarez-Torres, Sofía Latorre Redoli, Borja Martínez-Albardonedo, Marisel Araya-Rojas, Víctor Fajardo, Roberto T Abdala Díaz","doi":"10.3390/pharmaceutics17030335","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives</b>: This study explores the bioactive potential of <i>Bovistella utriformis</i> biomass and its polysaccharides (PsBu) through comprehensive biochemical and bioactivity analyses, focusing on their antioxidant, cytotoxic, and antihyperglycemic properties. <b>Methods</b>: Elemental analysis determined the biomass's chemical composition. Antioxidant activity was assessed using ABTS and DPPH assays. Monosaccharide composition was analyzed via gas chromatography-mass spectrometry (GC-MS). In vitro cytotoxicity assays were conducted on cancer and normal cell lines to determine IC<sub>50</sub> values and selectivity indices (SI). Zebrafish embryo toxicity was evaluated for teratogenic effects, and an in vivo antihyperglycemic study was performed in diabetic rat models. <b>Results</b>: The biomass exhibited high carbon content (around 41%) and nitrogen levels, with a balanced C/N ratio nearing 5. Protein content exceeded 50%, alongside significant carbohydrate, fiber, and ash levels. Antioxidant assays revealed inhibition rates of approximately 89% (ABTS) and 64% (DPPH). GC-MS analysis identified glucose as the predominant sugar (>80%), followed by galactose and mannose. Additionally, HPLC detected a photoprotective compound, potentially a mycosporin-like amino acid. Cytotoxicity assays demonstrated PsBu's selective activity against colon, lung, and melanoma cancer cell lines (IC<sub>50</sub>: 100-500 µg·mL<sup>-1</sup>), while effects on normal cell lines were lower (IC<sub>50</sub> > 1300 µg·mL<sup>-1</sup> for HaCaT, >2500 µg·mL<sup>-1</sup> for HGF-1), with SI values approaching 27, supporting PsBu's potential as a targeted anticancer agent. Zebrafish embryo assays yielded LC<sub>50</sub> values ranging from 1.4 to 1.8 mg·mL<sup>-1</sup>. In vivo, PsBu reduced fasting blood glucose levels in hyperglycemic rats (approximately 210 mg·dL<sup>-1</sup> vs. 230 mg·dL<sup>-1</sup> in controls) and preserved pancreatic β-cell integrity (around 80% vs. 65% in controls). <b>Conclusions</b>: These findings suggest that <i>B. utriformis</i> biomass and PsBu exhibit strong antioxidant activity, selective cytotoxicity against cancer cells, and antihyperglycemic potential, making them promising candidates for further biomedical applications.</p>","PeriodicalId":19894,"journal":{"name":"Pharmaceutics","volume":"17 3","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11946522/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/pharmaceutics17030335","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background/Objectives: This study explores the bioactive potential of Bovistella utriformis biomass and its polysaccharides (PsBu) through comprehensive biochemical and bioactivity analyses, focusing on their antioxidant, cytotoxic, and antihyperglycemic properties. Methods: Elemental analysis determined the biomass's chemical composition. Antioxidant activity was assessed using ABTS and DPPH assays. Monosaccharide composition was analyzed via gas chromatography-mass spectrometry (GC-MS). In vitro cytotoxicity assays were conducted on cancer and normal cell lines to determine IC50 values and selectivity indices (SI). Zebrafish embryo toxicity was evaluated for teratogenic effects, and an in vivo antihyperglycemic study was performed in diabetic rat models. Results: The biomass exhibited high carbon content (around 41%) and nitrogen levels, with a balanced C/N ratio nearing 5. Protein content exceeded 50%, alongside significant carbohydrate, fiber, and ash levels. Antioxidant assays revealed inhibition rates of approximately 89% (ABTS) and 64% (DPPH). GC-MS analysis identified glucose as the predominant sugar (>80%), followed by galactose and mannose. Additionally, HPLC detected a photoprotective compound, potentially a mycosporin-like amino acid. Cytotoxicity assays demonstrated PsBu's selective activity against colon, lung, and melanoma cancer cell lines (IC50: 100-500 µg·mL-1), while effects on normal cell lines were lower (IC50 > 1300 µg·mL-1 for HaCaT, >2500 µg·mL-1 for HGF-1), with SI values approaching 27, supporting PsBu's potential as a targeted anticancer agent. Zebrafish embryo assays yielded LC50 values ranging from 1.4 to 1.8 mg·mL-1. In vivo, PsBu reduced fasting blood glucose levels in hyperglycemic rats (approximately 210 mg·dL-1 vs. 230 mg·dL-1 in controls) and preserved pancreatic β-cell integrity (around 80% vs. 65% in controls). Conclusions: These findings suggest that B. utriformis biomass and PsBu exhibit strong antioxidant activity, selective cytotoxicity against cancer cells, and antihyperglycemic potential, making them promising candidates for further biomedical applications.
PharmaceuticsPharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
7.90
自引率
11.10%
发文量
2379
审稿时长
16.41 days
期刊介绍:
Pharmaceutics (ISSN 1999-4923) is an open access journal which provides an advanced forum for the science and technology of pharmaceutics and biopharmaceutics. It publishes reviews, regular research papers, communications, and short notes. Covered topics include pharmacokinetics, toxicokinetics, pharmacodynamics, pharmacogenetics and pharmacogenomics, and pharmaceutical formulation. Our aim is to encourage scientists to publish their experimental and theoretical details in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.